CIR circadian technologies limited
Add to My Watchlist 0.00% ! 31.0¢

ANP's ATL1103 Acromegaly Phase II Clinical Trial will complete...

  1. littlecorn
    6,402 Posts.
    lightbulb Created with Sketch. 181
    clock Created with Sketch.
    14/07/14
    11:03
    Post #: 13654911
    ANP's ATL1103 Acromegaly Phase II Clinical Trial will complete this week.
    24 patients have completed the full 13 weeks of dosing in the trial. The opportunity presented for the Company to enrol an additional 2 acromegalic patients into the trial (now 26 in total) who will receive their final dose of ATL1103 by 19 July 2014, which will mark the completion of all dosing in the trial.
    CIR Price at posting: 19.5¢ Sentiment: None Disclosure: Unspecified
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Strong soil results define new gold targets at Tole and Dadjan
right-arrow Created with Sketch.
NEWS Strategic investment secured for QLD and NSW bauxite projects
right-arrow Created with Sketch.
NEWS View the latest ASX market news here
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner
right-arrow Created with Sketch.
NEWS Drilling to commence at FAU’s Gimlet high-grade gold project following approvals
right-arrow Created with Sketch.
NEWS Marquee declares maiden antimony resource at Eastern Hills with phase two exploration to commence
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.